The annual cost of psoriasis

Background: The need for comparative cost figures for psoriasis therapy has become increasingly important. Objective: Our purpose was to compare the yearly costs of various psoriasis treatments. Methods: Ten patients were selected for each treatment modality and the average total cost per year, per...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 28; no. 3; pp. 422 - 425
Main Authors Sander, Hans M., Morris, Laura F., Phillips, Charles M., Harrison, Paul E., Menter, Alan
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.03.1993
Elsevier
Subjects
Adult
Biological and medical sciences
Cyclosporine - economics
Cyclosporine - therapeutic use
Dermatology
Etretinate - economics
Etretinate - therapeutic use
Female
Health Care Costs
Humans
Hydroxyurea - economics
Hydroxyurea - therapeutic use
Male
Medical sciences
Methotrexate - economics
Methotrexate - therapeutic use
Middle Aged
Phototherapy - economics
Psoriasis - economics
Psoriasis - therapy
Psoriasis. Parapsoriasis. Lichen
PUVA Therapy - economics
Retrospective Studies
Ultraviolet Therapy - economics
Human
Skin disease
Treatment
Psoriasis
Cost analysis
Health economy
Online AccessGet full text

Cover

More Information
Summary:Background: The need for comparative cost figures for psoriasis therapy has become increasingly important. Objective: Our purpose was to compare the yearly costs of various psoriasis treatments. Methods: Ten patients were selected for each treatment modality and the average total cost per year, per patient was evaluated. Results: All treatments evaluated were cheaper than inpatient therapy, with Goeckerman treatment in the day-care setting the most expensive and hydroxyurea the cheapest. Cyclosporine, which was used for comparison, was at least twice as expensive as all the other treatments except for Goeckerman treatment in the day-care setting, compared with which it was about 70% more expensive. Conclusion: No single treatment appears to be universally superior to others. In considering specific treatment for psoriasis, cost analyses, including appropriate laboratory and other specialized evaluations, must be taken into account. With use of these data, practitioners and health care organizations may be better able to select appropriate therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0190-9622
1097-6787
DOI:10.1016/0190-9622(93)70062-X